×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agendas
50 YEARS AFTER THALIDOMIDE – DEVELOPING DRUGS IN PREGNANCY
Session Chair(s)
Jordi Llinares Garcia, MS
Head of Research and Innovation
European Medicines Agency, Netherlands
Clinical, Ethical and Socioeconomic Considerations – an analysis in epilepsy, rheumatoid arthritis and schizophrenia
Learning Objective : 1. Recognise the drug safety and efficacy concerns for pregnant women suffering from epilepsy, rheumatoid arthritis and schizophrenia. 2. Analyse the effect of different therapeutic agents on disease activity, pregnancy outcomes and congenital anomalies. 3. Express the need for the development of treatment guidelines for these conditions in pregnancy.
Speaker(s)
Defining the Boundaries of the Current Regulatory Framework
Jordi Llinares Garcia, MS
European Medicines Agency, Netherlands
Head of Research and Innovation
How Does Industry Translate Experiences into a Way Forward?
Lode Dewulf
Corvalus, Belgium
Patient and Medical Affairs Consultant
Clinical, Ethical and Socioeconomic Considerations – an analysis in epilepsy, rheumatoid arthritis and schizophrenia
Victoria Tzouma, MS
MSD Greece, Greece
Market Access Manager
Have an account?